For the more than two million Americans living with type 1 diabetes, according to the American Diabetes Association, daily life revolves around a single missing function: the body’s ability to produce its own insulin. Decades of medical progress have made managing that gap safer and more precise, but managing a disease and curing it are not the same thing. Behind the scenes, a wave of stem cell research is now asking a more ambitious question, not how to manage type 1 diabetes more effectively, but how to restore the body’s own insulin production and remove the need for constant management altogether. That shift, from symptom management to a genuine prospective cure for type 1 diabetes, is what this new wave of stem cell research is chasing.
Where Diabetes treatment Stands Today
Insulin therapy remains the standard of care for type 1 diabetes, and for good reason: it is effective, well understood, and lifesaving. But it is also relentless. It requires constant monitoring, careful dosing, and daily administration, and it does nothing to address the underlying cause of the disease; the autoimmune destruction of the pancreas’s insulin-producing beta cells.
Islet transplantation, in which insulin-producing cells from a donor pancreas are transferred into a patient, comes closer to a genuine functional cure. When successful, it can restore natural insulin production and in some cases eliminate the need for injections entirely. But the approach is fundamentally limited by donor scarcity. Additionally, patients typically require lifelong immunosuppressive drugs to prevent rejection, and these medications carry their own long-term risks. It’s a meaningful option for some, but not one that can scale to meet the needs of the broader type 1 diabetes population.
The gap between managing symptoms and restoring function, and between a treatment that works for some patients and one that could work at scale, is where stem cell research has entered the picture.
What Would a Cure Actually Require?
It’s worth being precise about what a functional cure for type 1 diabetes would actually mean. It isn’t simply better symptom control. A true functional cure would restore the body’s own ability to sense blood sugar and produce the right amount of insulin in response, without daily injections, without constant monitoring, and ideally without a lifetime of immunosuppressive medication.
That’s a high bar, and no therapy has cleared it yet for widespread clinical use. Several research programs are working toward it from different angles, each attempting to solve the same underlying problem: how to replace the beta cells the immune system has destroyed, safely and at scale. Regenerative Medical Solutions (RMS) is one of the organizations pursuing this goal; our current work toward a prospective cure for diabetes is focused specifically on this challenge, and is a useful example of where the science currently stands.
How Stem Cell Science is Approaching a Prospective Cure
The most active area of this research relies on induced pluripotent stem cells, or iPSCs. Scientists produce them by taking mature adult cells, often from skin or blood, and coaxing them back into an earlier, more flexible state. From there, those reprogrammed cells can be directed down new developmental paths, including toward becoming insulin-producing beta cells. Starting from adult tissue rather than embryos sidesteps the ethical debate that surrounds embryonic stem cell research, and since the source material can come from a patient’s own body, iPSCs open up a donor-free alternative to islet transplantation, one that could in principle scale well beyond what donor organs alone would ever allow.
Turning iPSCs into functioning, insulin-responsive beta cells in the lab is a complex, multi-step process, and it’s an area of active refinement across the research community. Many of the therapies furthest along in development still depend on immunosuppressive drugs or an implantable device to protect the transplanted cells from immune attack. Solving that piece of the puzzle (achieving durable insulin production without those additional burdens) is widely considered the next major milestone in the field.
RMS’s Approach and Progress
RMS’s research, which grew out of over 15 years of academic work in Dr. Jon Odorico’s laboratory at the University of Wisconsin–Madison, is built around this challenge. RMS has developed a proprietary process for converting human iPSCs into islet-like clusters (ILCs), insulin-producing cell structures designed to replicate the function of the beta cells that are lost. This represents a meaningful step toward a prospective cure for type 1 diabetes.
RMS’s approach is currently in preclinical development, with an Investigational New Drug (IND) application in preparation as the next step toward human clinical trials. The program has been supported by NIH grant funding and is built on a foundation of issued patents. Like much of the field, RMS’s work is still in development, but the direction of the research reflects where the broader search for a prospective cure for type 1 diabetes is headed: toward therapies that could one day restore natural insulin production without lifelong immunosuppression or reliance on scarce donor tissue.
What’s Next in Cure-track Research
Type 1 diabetes research is entering a period of real momentum. The scientific and regulatory groundwork being laid today is what will determine how quickly a genuine functional cure becomes available to patients rather than remaining a research goal.
There is no approved stem cell cure for type 1 diabetes available today, and legitimate research in this space is measured in years, not months. But the underlying science (reprogrammed stem cells, lab-grown beta cells, and therapies designed to work without lifelong immunosuppression) represents one of the most credible paths toward a prospective cure for type 1 diabetes that current medicine has to offer.
To find out more about our progress toward that goal, including updates on preclinical milestones and the path toward clinical trials, contact us today.
Frequently Asked Questions About Curing Type 1 Diabetes
Is there a cure for type 1 diabetes? For most patients, there is no cure for type 1 diabetes that is readily accessible. However, islet transplantation, which uses insulin-producing cells from a donor pancreas, can restore natural insulin production and has effectively cured some patients of type 1 diabetes. Unfortunately, donor scarcity and the need for lifelong immunosuppressive drugs mean it isn’t a realistic option for the vast majority of people with the disease. Insulin therapy remains the standard treatment for nearly everyone else, managing blood sugar without restoring the body’s own insulin production. Stem cell research, including RMS’s own work, is advancing toward a functional cure designed to be accessible at a much larger scale. RMS’s prospective cure does not require immunosuppressive drugs.
Will there ever be a cure for diabetes? Most researchers believe a functional cure for diabetes, one that restores the body’s own insulin production, is achievable, and progress has accelerated in recent years thanks to advances in induced pluripotent stem cell (iPSC) research. No cure exists today, but the science has moved the question from “if” to “when.”